Bryce Point Capital LLC Makes New $601,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Bryce Point Capital LLC acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 4th quarter, Holdings Channel reports. The firm acquired 23,790 shares of the biopharmaceutical company’s stock, valued at approximately $601,000.

Other hedge funds have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its holdings in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics in the fourth quarter worth $81,000. KBC Group NV boosted its position in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 1,647 shares during the last quarter. AlphaQuest LLC grew its stake in Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 2,705 shares in the last quarter. Finally, E Fund Management Co. Ltd. bought a new stake in Celldex Therapeutics in the 4th quarter valued at $273,000.

Celldex Therapeutics Stock Up 3.1 %

NASDAQ CLDX opened at $17.38 on Thursday. Celldex Therapeutics, Inc. has a 52 week low of $16.40 and a 52 week high of $47.00. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -6.76 and a beta of 1.76. The company has a fifty day moving average of $21.49 and a two-hundred day moving average of $25.81.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on CLDX. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday, February 28th. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. The Goldman Sachs Group decreased their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. UBS Group started coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 target price for the company. Finally, Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They issued an “overweight” rating and a $46.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $54.33.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.